{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:02:26Z","timestamp":1789718546462,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hubei Provincial Administration of Traditional Chinese Medicine Traditional Chinese Medicine Research Project","award":["ZY2023F054"],"award-info":[{"award-number":["ZY2023F054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05213-8","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:23:46Z","timestamp":1782555826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated single-cell RNA sequencing and mendelian randomization reveals the role of resting regulatory T cells in skin melanoma prognosis"],"prefix":"10.1007","volume":"17","author":[{"given":"Yadong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caidie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"21","key":"5213_CR1","doi-asserted-by":"publisher","first-page":"e70386","DOI":"10.1002\/cam4.70386","volume":"13","author":"IJ Tan","year":"2024","unstructured":"Tan IJ, Parikh AK, Cohen BA. Melanoma metabolism: molecular mechanisms and therapeutic implications in cutaneous oncology. Cancer Med. 2024;13(21):e70386.","journal-title":"Cancer Med"},{"issue":"12","key":"5213_CR2","first-page":"1838","volume":"65","author":"SC Dougherty","year":"2024","unstructured":"Dougherty SC, Flowers WL, Gaughan EM. Precision oncology in melanoma: changing practices. J Nucl Med. 2024;65(12):1838\u201345.","journal-title":"J Nucl Med"},{"issue":"2","key":"5213_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40257-024-00910-y","volume":"26","author":"R Reschke","year":"2025","unstructured":"Reschke R, Enk AH, Hassel JC. Prognostic biomarkers in evolving melanoma immunotherapy. Am J Clin Dermatol. 2025;26(2):213\u201323.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"5213_CR4","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3390\/cancers15061697","volume":"15","author":"G Cazzato","year":"2023","unstructured":"Cazzato G, Cascardi E, Colagrande A, Lettini T, Filosa A, Arezzo F, et al. T cell immunoglobulin and mucin domain 3 (tim-3) in cutaneous melanoma: a narrative review. Cancers. 2023;15(6):1697.","journal-title":"Cancers"},{"issue":"Suppl 1","key":"5213_CR5","first-page":"47","volume":"5","author":"SY Li","year":"2013","unstructured":"Li SY, Liu Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol Adv Appl. 2013;5(Suppl 1):47\u201353.","journal-title":"Clin Pharmacol Adv Appl"},{"issue":"3","key":"5213_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13402-020-00501-z","volume":"43","author":"H Bagheri","year":"2020","unstructured":"Bagheri H, Pourhanifeh MH, Derakhshan M, Mahjoubin-Tehran M, Ghasemi F, Mousavi S, et al. CXCL-10: a new candidate for melanoma therapy? Cell Oncol. 2020;43(3):353\u201365.","journal-title":"Cell Oncol"},{"issue":"1","key":"5213_CR7","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1038\/s41467-023-39817-3","volume":"14","author":"M Haake","year":"2023","unstructured":"Haake M, Haack B, Sch\u00e4fer T, Harter PN, Mattavelli G, Eiring P, et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat Commun. 2023;14(1):4253.","journal-title":"Nat Commun"},{"key":"5213_CR8","doi-asserted-by":"crossref","unstructured":"Soumoy L, Kindt N, Ghanem G, Saussez S, Journe F. Role of macrophage migration inhibitory factor (MIF) in melanoma, Cancers .2019;11(4).","DOI":"10.3390\/cancers11040529"},{"issue":"1","key":"5213_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41416-020-01159-y","volume":"124","author":"PR Kumar","year":"2021","unstructured":"Kumar PR, Moore JA, Bowles KM, Rushworth SA, Moncrieff MD. Mitochondrial oxidative phosphorylation in cutaneous melanoma. Br J Cancer. 2021;124(1):115\u201323.","journal-title":"Br J Cancer"},{"issue":"1","key":"5213_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12964-025-02267-z","volume":"23","author":"KY Huang","year":"2025","unstructured":"Huang KY, Ng KF, I KY, Chang YC, Chen HY, Chiu YF, et al. GPR56\/ADGRG1 induces biased Rho-ROCK-MLC and JAK-STAT3 signaling to promote amoeboid-like morphology and IL-6 upregulation in melanoma cells. Cell Commun Signal. 2025;23(1):251.","journal-title":"Cell Commun Signal"},{"key":"5213_CR11","doi-asserted-by":"publisher","first-page":"107327482110515","DOI":"10.1177\/10732748211051554","volume":"29","author":"R Huang","year":"2022","unstructured":"Huang R, Li M, Zeng Z, Zhang J, Song D, Hu P, et al. The identification of prognostic and metastatic alternative splicing in skin cutaneous melanoma. Cancer Control. 2022;29:10732748211051554.","journal-title":"Cancer Control"},{"key":"5213_CR12","doi-asserted-by":"publisher","first-page":"906043","DOI":"10.3389\/fphar.2022.906043","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Otkur W, Wang A, Wang W, Lyu Y, Fang L, et al. Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway. Front Pharmacol. 2022;13:906043.","journal-title":"Front Pharmacol"},{"issue":"3","key":"5213_CR13","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/ijms25031582","volume":"25","author":"F Cassalia","year":"2024","unstructured":"Cassalia F, Danese A, Tudurachi I, Federico S, Zambello A, Guidotti A, et al. PRAME updated: diagnostic, prognostic, and therapeutic role in skin cancer. Int J Mol Sci. 2024;25(3):1582.","journal-title":"Int J Mol Sci"},{"issue":"46","key":"5213_CR14","doi-asserted-by":"publisher","first-page":"17487","DOI":"10.1074\/jbc.RA119.010149","volume":"294","author":"SD Ha","year":"2019","unstructured":"Ha SD, Cho W, DeKoter RP, Kim SO. The transcription factor PU.1 mediates enhancer-promoter looping that is required for IL-1\u03b2 eRNA and mRNA transcription in mouse melanoma and macrophage cell lines. J Biol Chem. 2019;294(46):17487\u2013500.","journal-title":"J Biol Chem"},{"issue":"1","key":"5213_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13059-021-02308-z","volume":"22","author":"J Yu","year":"2021","unstructured":"Yu J, Chai P, Xie M, Ge S, Ruan J, Fan X, et al. Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22(1):85.","journal-title":"Genome Biol"},{"issue":"5","key":"5213_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3892\/ijmm.2022.5122","volume":"49","author":"M Schott","year":"2022","unstructured":"Schott M, Kappelmann-Fenzl M, Fischer S, Fernandez-Barrena MG, Pineda-Lucena A, \u00c1vila MA, et al. Impact of CYLD on chromatin structure and histone methylation in malignant melanoma. Int J Mol Med. 2022;49(5):66.","journal-title":"Int J Mol Med"},{"issue":"3","key":"5213_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/eji.202048747","volume":"51","author":"ZN Willsmore","year":"2021","unstructured":"Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021;51(3):544\u201356.","journal-title":"Eur J Immunol"},{"issue":"6","key":"5213_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","volume":"27","author":"L Spain","year":"2016","unstructured":"Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27(6):1135\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"5213_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12967-019-1862-y","volume":"17","author":"H Paz","year":"2019","unstructured":"Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, et al. Interleukin 32 expression in human melanoma. J Transl Med. 2019;17(1):113.","journal-title":"J Transl Med"},{"key":"5213_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5416843","volume":"2020","author":"M Cioplea","year":"2020","unstructured":"Cioplea M, Nichita L, Georgescu D, Sticlaru L, Cioroianu A, Nedelcu R, et al. FOXP3 in melanoma with regression: between tumoral expression and regulatory T cell upregulation. J Immunol Res. 2020;2020:5416843.","journal-title":"J Immunol Res"},{"issue":"14","key":"5213_CR21","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1002\/cam4.3963","volume":"10","author":"C Zhang","year":"2021","unstructured":"Zhang C, Dang D, Cong L, Sun H, Cong X. Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis. Cancer Med. 2021;10(14):4710\u201320.","journal-title":"Cancer Med"},{"issue":"2","key":"5213_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1684\/ejd.2010.1240","volume":"21","author":"CA Pepe","year":"2011","unstructured":"Pepe CA, Ricci R, Cortelazzi C, Mori G, Zambito F, Campanini N, et al. The vast majority of lymphocytes infiltrating primary cutaneous melanoma express the CD27 costimulatory receptor: implications for melanoma progression. Eur J Dermatol. 2011;21(2):178\u201383.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"5213_CR23","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","volume":"11","author":"DH Peng","year":"2020","unstructured":"Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, et al. Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020;11(1):4520.","journal-title":"Nat Commun"},{"issue":"1","key":"5213_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000533932","volume":"240","author":"S Naimy","year":"2024","unstructured":"Naimy S, Bzorek M, Eriksen JO, L\u00f8vendorf MB, Litman T, Dyring-Andersen B, et al. LAG3 and TIGIT expression on tumor-infiltrating lymphocytes in cutaneous melanoma. Dermatology (Basel, Switzerland). 2024;240(1):156\u201363.","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"2","key":"5213_CR25","doi-asserted-by":"publisher","first-page":"100179","DOI":"10.1016\/j.xjidi.2022.100179","volume":"3","author":"J Han","year":"2023","unstructured":"Han J, Correa da Rosa J, Agarwal A, Owji S, Yassky D, Luu Y, et al. Modulation of inflammatory proteins in serum may reflect cutaneous immune responses in cancer immunotherapy. JID Innov. 2023;3(2):100179.","journal-title":"JID Innov"},{"issue":"5","key":"5213_CR26","first-page":"735","volume":"211","author":"B Thompson","year":"2023","unstructured":"Thompson B, Strange A, Amato CM, Hester-McCullough J, Sarnaik AA, Weber JS, et al. CD4 phenotypes are associated with reduced expansion of tumor-infiltrating lymphocytes in melanoma patients treated with adoptive cell therapy. J Invest Med. 2023;211(5):735\u201342.","journal-title":"J Invest Med"},{"issue":"2","key":"5213_CR27","doi-asserted-by":"publisher","first-page":"e001906","DOI":"10.1136\/jitc-2020-001906","volume":"9","author":"M Chelvanambi","year":"2021","unstructured":"Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer. 2021;9(2):e001906.","journal-title":"J Immunother Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05213-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05213-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05213-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:12:47Z","timestamp":1789715567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05213-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5213"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05213-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1353"}}